{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:13:50Z","timestamp":1770066830270,"version":"3.49.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.juro.2017.05.072","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T03:45:56Z","timestamp":1496029556000},"page":"1054-1060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study"],"prefix":"10.1097","volume":"198","author":[{"given":"Bertrand","family":"Tombal","sequence":"first","affiliation":[{"name":"Cliniques Universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik B.","family":"Cornel","sequence":"additional","affiliation":[{"name":"Department of Urology, Ziekenhuisgroep Twente, Hengelo, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Persad","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Bristol National Health Service Foundation Trust, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anny","family":"Stari","sequence":"additional","affiliation":[{"name":"Astellas Pharma Medical Affairs EMEA, Chertsey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"G\u00f3mez Veiga","sequence":"additional","affiliation":[{"name":"Salamanca University Hospital and Translational Research Group of Urology GITUR-IBSAL, Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Schulman","sequence":"additional","affiliation":[{"name":"Clinic E Cavell and University of Brussels, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.05.072_bib1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.05.072_bib2","unstructured":"Mottet N, Bellmunt J, Briers E et\u00a0al: European Association of Urology Guidelines on Prostate Cancer. Updated March 2016. Available at http:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed February 28, 2017."},{"key":"10.1016\/j.juro.2017.05.072_bib3","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1111\/j.1464-410X.2012.11190.x","article-title":"Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?","volume":"110","author":"Pickles","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2017.05.072_bib4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.05.072_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0022-5347(05)00161-8","article-title":"A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer","volume":"175","author":"Crawford","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.05.072_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/pcan.2008.52","article-title":"Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe","volume":"12","author":"Tunn","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.juro.2017.05.072_bib7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.eururo.2015.10.007","article-title":"Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND)","volume":"69","author":"Schulman","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.05.072_bib8","unstructured":"Roche Diagnostics: Electrochemiluminescence Immunoassay (ECLIA) for the in\u00a0Vitro Quantitative Determination of Testosterone in Human Serum and Plasma. Updated 2012. Available at http:\/\/www.roche-diagnostics.ch\/content\/dam\/corporate\/roche-dia_ch\/documents\/broschueren\/professional_diagnostics\/serumarbeitsplatz\/immunologie\/fertilitaet-hormone\/EN_Testosteron%20II_FactSheet.pdf. Accessed May 8, 2017."},{"key":"10.1016\/j.juro.2017.05.072_bib9","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","article-title":"Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy","volume":"178","author":"Morote","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.05.072_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0090-4295(00)00793-7","article-title":"Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making","volume":"56","author":"Oefelein","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.05.072_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clgc.2013.01.002","article-title":"Effects of serum testosterone levels after 6 months of\u00a0androgen deprivation therapy on the outcome of patients with prostate cancer","volume":"11","author":"Bertaglia","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.juro.2017.05.072_bib12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.2009.08814.x","article-title":"Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?","volume":"105","author":"Perachino","year":"2010","journal-title":"BJU Int"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.05.072_bib13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eursup.2007.04.001","article-title":"Optimal testosterone control and eligard","volume":"6","author":"Tombal","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.05.072_bib14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471774503X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002253471774503X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.05.072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:03:12Z","timestamp":1651208592000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.05.072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1016\/j.juro.2017.05.072"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.05.072","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.05.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}